P roton pump inhibitors (PPIs) are widely prescribed. With more than four million prescriptions in Canada in 2010, eso meprazole became the sixth most commonly pre scribed drug in the country. 1 In the United States, the situation is similar, with more than 15 million patients prescribed PPIs in 2013, 2 at an estimated cost of US$79 billion between 2007 and 2011. 3 Use may be even more common, because omeprazole has been approved in the US and Canada for shortterm overthecounter use.
In general, PPIs are safe and have several wellestablished and evidencebased indications (Appendix 1, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.150570//DC1). There are many patients, including older adults taking concomitant nonsteroidal antiinflammatory drugs, steroids or antiplatelet agents, who require longterm prophylaxis with PPIs to decrease their risk of gastrointestinal hemorrhage. However, be cause PPIs are generally well tolerated, they have been increasingly prescribed for common gastro intestinal symptoms beyond evidencebased indi cations. Furthermore, as suggested by the Can adian Association of Gastroenterology, 4 many patients receive longterm PPI therapy and can benefit from periodic reassessment. 5 Proton pump inhibitors are associated with a number of rare but potentially serious adverse effects. These uncommon effects become highly relevant when considering the tens of millions of patients who take PPIs worldwide. Recognizing some of these harms, the US Food and Drug Administration (FDA) and Health Canada have issued safety advisories regarding the use of PPIs related to Clostridium difficile, fracture risk and profound hypomagenesemia. [6] [7] [8] [9] In this review, we present the potential harms that should be considered when physicians and pa tients weigh the risks and benefits of starting or continuing longterm PPI therapy (Box 1). The available evidence for the potential harms of PPIs comprises observational studies. As is usual with such studies that identify rare events, association is shown, but causation cannot be proven. Even the best observational studies have a risk of bias owing to residual confounding or other methodologic is sues. Nonetheless, it remains prudent to follow Health Canada's advice that "PPIs should be pre scribed at the lowest dose and shortest duration of therapy appropriate to the condition being treated." 9 In keeping with the tenets of the Choosing Wisely Canada campaign (Box 2), 4 new PPI prescriptions ought to be for evidencebased indications, contin uous PPI use should be reevaluated regularly, and patients should be counselled on possible compli cations when contemplating longterm therapy.
For this review, we have divided the potential harms into three types: drug interactions, non infectious complications and infectious complica tions. Where possible, we have included the esti mated number needed to harm (NNH). Although not the focus of the review, Appendix 1 provides evidencebased indications for PPI initiation as well as common reasons why the treatment is prescribed without supporting evidence. who received clopidogrel after myocardial in farction showed that concurrent use of omepra zole was associated with an increased risk of re current myocardial infarction within 90 days after the index event (odds ratio [OR] 1.27, 95% confidence interval [CI] 1.03-1.57); the associa tion was not seen with pantoprazole (OR 1.02, 95% CI 0.70-1.47). 10 A systematic review and metaanalysis of 25 studies involving 159 138 patients showed that concurrent use of PPIs and clopidogrel was associated with a 29% increased relative risk of combined major cardiovascular events (95% CI 15%-45%) and a 31% increased relative risk of myocardial infarction (95% CI 12%-15%), without an influence on mortality (risk ratio 1.04, 95% CI 0.93-1.16).
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In contrast, a withinperson case-control study involving 24 471 patients showed that PPI use was associated with an increased risk of death or incident myocardial infarction in tradi tional cohort analysis (hazard ratio [HR] 1.37, 95% CI 1.27-1.48); however, the investigators found no association when they compared indi vidual patients at times when they were using PPIs with times when they were not (rate ratio 0.75, 95% CI 0.55-1.01). 12 The authors suggest this indicates residual confounding in the tradi tional an alyses. Furthermore, the Clopidogrel with or without Omeprazole in Coronary Artery Disease (COGENT) trial, a randomized, pla cebocontrolled, doubleblind study, evaluated the combination of acetylsalicylic acid, clopido grel and omeprazole (a proprietary combination tablet in which clopidogrel and omeprazole were released at different times) in patients with an indication for dual antiplatelet therapy. 13 Al though the trial showed that omeprazole pre vented overt upper gastrointestinal bleeding (number needed to treat = 200), an association between PPI use and incident myocardial infarc tion was not found. Nonetheless, the authors concluded that they "could not exclude a clini cally meaningful difference in cardiovascular events due to omeprazole."
The debate now centres on whether PPI use is really a marker for an atrisk population (con founding by indication) rather than causally asso ciated with myocardial infarction. Regardless, the FDA suggests to "avoid concomitant use of esomeprazole/omeprazole with clopidogrel." 14 For patients who require clopidogrel and ongoing PPI therapy, one could consider other PPIs.
Other medications
Therapeutic levels of numerous other drugs have been shown both in vitro and in vivo to be influ enced by PPI use. Studies have shown that omeprazole carries a considerable potential for drug interactions because of its high affinity for cytochrome P450 2C19 and a moderate affinity for cytochrome P450 3A4. 15 Other PPIs are believed to have less of an affinity, and interac tions are not as potent. Medications such as thy roid hormone replacement drugs, chemotherapy drugs (e.g., methotrexate 16 ), antifungals and anti retroviral agents may be subject to interaction. The concurrent use of PPIs and certain antiretrovi ral agents may lead to inadequate drug exposure if the interactions are not properly managed.
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What are the most important noninfectious adverse events?
Rebound hyperacidity
In two randomized controlled trials (RCTs) involving healthy volunteers given four to eight weeks of PPI therapy, 18, 19 dyspepsia occurred in 20% to 44% of participants after discontinuation of the PPI and was associated with elevated lev els of gastrin and chromogrammin A. This rebound acid hypersecretion may require a taper ing off of PPIs in patients who have been on longterm therapy.
Malabsorption of vitamin B 12 , iron and magnesium
By altering intragastric pH levels, PPIs decrease the absorption of vitamin B 12 and nonheme iron. A systematic review of observational studies suggested that longterm use of PPIs for more
Box 1: Evidence used in this review
We used national guidelines from the Canadian Association of Gastroenterology, the American College of Gastroenterology, the American Association for the Study of Liver Diseases to identify guideline-and evidencebased indications for the use of PPIs and the recommended duration of therapy. We searched PubMed using the following terms: "proton pump inhibitor," "PPI," "safety," "side-effects," "adverse events" and selected randomized control trials, observational studies, systematic reviews and meta-analyses. Other relevant articles were manually retrieved from the reference lists of selected articles. Health Canada and US Food and Drug Administration advisories were also searched for "Proton Pump Inhibitors." Box 2: Choosing Wisely Canada recommendation on proton pump inhibitor (PPI) therapy than two years is associated with an increased risk of vitamin B 12 deficiency (HR 1.83, 95% CI 1.36-2.46). 20 With a 10% estimated baseline risk of vitamin B 12 deficiency in older patients, the NNH for one year of use would be four pa tients. 21 No recommendations exist regarding testing for vitamin B 12 deficiency in older pa tients receiving longterm PPI therapy; however, judicious use in highrisk patients is reasonable.
One study of the impact of PPIs on iron ab sorption has shown that response to oral iron re placement therapy after two months of PPI ther apy is reduced in select patients taking PPIs who have no evident source of blood loss. 22 Another retrospective cohort study has shown that pa tients taking PPIs have a decreased hemoglobin level and mean corpuscular volume. 23 Use of PPIs has been associated with an increased risk of severe hypomagnesemia among communitydwelling patients (OR 3.79, 95% CI 2.99-4.82; NNH = 73). 24 Hypomagnesemia is most common in patients who have taken PPIs for more than five years. 25 Severe hypomagnese mia can cause serious adverse events, including tetany, seizures and arrhythmias. Consequently, the FDA has recommended that atrisk cardiac patients requiring ongoing PPI use have their magnesium level verified periodically.
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Osteoporosis Several metaanalyses and systematic reviews based on observational data have shown an asso ciation between recent and chronic PPI use and the risk of fractures in both men and women. 27, 28 In contrast, this association has not been shown with use of histamine2 receptor antagonists. 28 Assuming a baseline risk of 1.5 per 1000 patient years for hip fractures and 6 per 1000 patient years for vertebral fractures, the NNH would be 2672 and 337, respectively. 29 It is postulated that PPIs reduce the oral bioavailability of calcium and that hypergastrinemia and mild hypomagne semia stimulate parathyroid hormone production leading to increased bone resorption. Another hypothesis is that PPIs inhibit osteoclast proton pumps, leading to increased osteoclast activity and direct alteration of bone metabolism.
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Acute interstitial nephritis A prospective multicentre study from France of druginduced acute interstitial nephritis and a retrospective study from the US determined that PPIs were the culprit in 16.7% and 14% of cases, respectively. 31, 32 A nationwide nested casecontrol study from New Zealand estimated that, for every 100 000 current PPI users more than 60 years of age, there were about 20 cases of acute interstitial nephritis per year (NNH = 5000). 33 The incidence of this adverse event is low; therefore, a high index of suspicion is required to make the diagnosis and stop the offending medication.
Dementia and functional decline
An observational study of data derived from the German Study on Aging, Cognition and Demen tia in Primary Care Patients (n = 3076) showed that PPI use was associated with an increased incidence of any dementia (HR 1.38, 95% CI 1.04-1.83; p = 0.02) and specifically Alzheimer dementia (HR 1.44; 95%CI 1.01-2.06) after adjustment for potential confounding factors. 34 Two hypotheses exist for the possible mecha nism. First, lansoprazole has been shown to enhance production of amyloid β protein, which is implicated in the pathogenesis of Alzheimer disease. 35 Second, gastrinreleasing peptide is elevated in PPI users and has been shown to modulate brain functions related to stress and anxiety.
In addition to dementia, PPI use was also associated, after adjustment, with increased functional impairment (OR 2.44, 95% CI 1.36-4.41; NNH = 15) and mortality (HR 1.51, 95% CI 1.03-2.77) in frail older patients discharged from hospital with a PPI prescription. 36, 37 What are the most important infectious complications?
Clostridium difficile-associated diarrhea and other enteric infections Clostridium difficile-associated diarrhea causes substantial morbidity and mortality. A large metaanalysis involving 23 studies and 272 636 patients from around the world showed that PPI use was associated with an increased relative risk of C. difficile by as much as 69% (risk ratio 1.69, 95% CI 1.40-1.97). 38 There was no signif icant heterogeneity between the studies in cluded, and after a conservative adjustment for potential publication bias, the association re mained significant (risk ratio 1.26, 95% CI 1.03-2.24). The NNH among community dwelling patients with one year of PPI use has been estimated to be 3925, decreasing to 50 at 14 days among patients in hospital receiving an tibiotics. 39 Use of PPIs has also been shown to increase the risk of recurrence of C. difficile (HR 1.5, 95% CI 1.1-2.0), and yet few patients have their PPI stopped during an episode of C. difficile despite nearly 50% of ongoing use being potentially inappropriate. 40 Use of PPIs is associated with an increased Review risk of other bacterial enteric infections, as was shown in a metaanalysis of five studies (OR 3.33, 95% CI 1.84-6.02). 41 The pathogens most often isolated were Campylobacter and Salmonella spe cies. There is also limited and theoretical evidence that PPI use may be related to traveller's diarrhea and to infections caused by Vibrio cholerae and Listeria monocytogenes.
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Spontaneous bacterial peritonitis
Spontaneous bacterial peritonitis can occur in patients with cirrhosis and ascites and is an im portant cause of morbidity and mortality. Bacte rial translocation is thought to play a key role in its pathogenesis and is hypothesized to increase in patients receiving PPIs. Two metaanalyses, involving 772 and 3815 patients, respectively, showed that the odds of spontaneous peritonitis were increased two to threefold among people taking PPIs (NNH = 9), without significant evi dence of heterogeneity. 43, 44 Patients in whom peritonitis develops frequently have no clear in dication for continued PPI use. 45 Therefore, in accordance with the American Association for the Study of Liver Diseases guidelines, 46 PPIs should be used with caution in patients with cir rhosis and be reserved for an appropriate dura tion of therapy in patients with peptic ulcer dis ease, or for a short period following esophageal variceal ligation. 
Pneumonia
Many studies have tried to characterize the associ ation between PPIs and the risk of both hospital and communityacquired pneumonia. Herzig and colleagues 47 performed a prospective cohort study and identified PPI use as a risk factor for hospital acquired pneumonia (OR 1.3, 95% CI 1.1-1.4; NNH = 111). A metaanalysis that included 23 RCTs and 8 nonrandomized studies showed that PPIs were associated with an increased risk of allcause pneumonia in a randomeffects model to correct for heterogeneity (OR 1.27, 95% CI 1.11-1.46). 48 The risk was higher for community acquired pneumonia (OR 1.34, 95% CI 1.14-1.57), was highest within 7 days after the start of PPI use (OR 3.96, 95% CI 2.86-5.45) and per sisted up to 180 days after the start of treatment (OR 1.36, 95% CI 1.05-1.78).
One important limitation of these studies is that they did not adjust for gastresophageal reflux disease, which itself may be associated with both PPI use and pneumonia. Using a data base of eight separate cohort studies involving patients 40 years or older who were new users of nonsteroidal antiinflammatory drugs, Filion and colleagues 49 showed that PPIs did not increase the risk of hospital admission for community acquired pneumonia in a fixedeffect meta analytic model. The authors concluded that the association between PPIs and pneumonia may constitute a protopathic bias. Nevertheless, pneu monia remains a frequent cause of morbidity, hospital admission and mortality, and therefore it is prudent to minimize any additional risk of pneumonia by avoiding inappropriate PPI use.
How can inappropriate PPI use be avoided or stopped?
Several strategies have been developed to mini mize PPI use; however, larger studies are required to determine their effectiveness. One strategy paired a 20minute educational session on the benefits and harms of PPI use with a Web based tool cueing medical residents to reassess the appropriateness of PPI prescriptions for medi cal inpatients. 5 A total of 49% of patients without a clear indication for treatment had their PPI stopped before hospital discharge. Another strat egy involved a nurseled dyspepsia clinic in which a nursing team developed action plans with patients to stop unnecessary PPI use. 50 At three months, 64% of the 157 patients had stopped their PPI and another 30% were taking a reduced dose. Patients who have been taking a PPI at high dose for prolonged durations may experience rebound hyperacidity, and a tapering regimen or stepdown to an histamine2 receptor blocker may help offset these symptoms.
Before prescribing a new PPI, physicians may want to consider whether the patient has an evi dencebased indication for the treatment. In Ap pendix 1, we provide several evidencebased in dications for continuous PPI therapy, as well as some common indications for which PPI treat ment is often started but is not supported by the available evidence. For patients who have symp toms of gastresophageal reflux disease, a trial of nonpharmacologic interventions (e.g., avoiding large meals before bedtime, and decreasing caf feine and alcohol consumption) should be con sidered. Alternatively, a histamine2 recepter blocker or overthecounter antacids could be tried before prescribing the most potent available treatment. In patients who are prescribed a PPI, the use should not be indefinite without regular attempts to taper when symptoms are controlled for three months.
By avoiding use outside of the evidence base, maximizing lifestyle interventions and regularly reassessing the indication for longterm PPI use, physicians can minimize PPI exposure and con sequently the risk of rare, but important, adverse effects.
Conclusion
The main action of PPIs is a pronounced and longlasting effect on gastric acid production, which makes this class of drugs a highly effective treatment option for various acidrelated disor ders. However, their use has become very com mon and has expanded beyond the evidence base. This has led to increased drug costs and an evolv ing understanding of the adverse events associ ated with longterm use. Although gaps in knowl edge remain (Box 3), we believe that Health Canada's advice, that PPIs should be prescribed at the lowest dose and for the shortest duration of therapy appropriate to the condition being treated, reflects best practice and follows the te nets of the Choosing Wisely Canada campaign (Box 2). 4 We encourage patients and their physi cians to have regular discussions about the risks and benefits of PPI therapy and to use this review as a reference for shared decisionmaking.
